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Abstract: Pharmacological Hedgehog (Hh) pathway inhibition has emerged as a valuable 
anticancer strategy. A number of small molecules able to block the pathway at the upstream 
receptor Smoothened (Smo) or the downstream effector glioma-associated oncogene 1 (Gli1) has 
been designed and developed. In a recent study, we exploited the high versatility of the natural 
isoflavone scaffold for targeting the Hh signaling pathway at multiple levels showing that the 
simultaneous targeting of Smo and Gli1 provided synergistic Hh pathway inhibition stronger than 
single administration. This approach seems to effectively overcome the drug resistance, 
particularly at the level of Smo. Here, we combined the pharmacophores targeting Smo and Gli1 
into a single and individual isoflavone, compound 22, which inhibits the Hh pathway at both 
upstream and downstream level. We demonstrate that this multitarget agent suppresses 
medulloblastoma growth in vitro and in vivo through antagonism of Smo and Gli1, which is a 
novel mechanism of action in Hh inhibition. 
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1. Introduction 
Hedgehog (Hh) signaling is a developmental pathway involved in tissue homeostasis, cell 
stemness and tumorigenesis [1–4]. The Hh pathway activity is controlled by Hh ligands and the 
transmembrane receptors, Patched1 (Ptch1) and Smoothened (Smo), that are endowed with 
inhibitory and activator function, respectively. In the absence of Hh ligand, Ptch1 represses Smo 
keeping the pathway off. In the presence of ligand, Ptch1 relieves Smo-derived signals that activate 
Gli transcription factors, thus, promoting proliferation, survival and cell migration. Aberrant 
activation of the Hh pathway has been found in a wide spectrum of tumors, such as basal cell 
carcinoma (BCC) and medulloblastoma (MB) [5], and its deregulation can alter cancer stem cells 
features (i.e., self-renewal, survival, neoangiogenesis, metastatic spread) [6–9]. For this reason, Hh 
pathway represents an attractive target for anticancer therapy nowadays [10–12]. 
Many Hh-dependent human cancers are driven by an inappropriate upstream pathway 
activation (i.e., loss-of-function mutations of Ptch1 receptor, gain-of-function mutations involving 
Smo receptor, Hh ligand overproduction) [13,14]; that is why most of the Hh inhibitors developed 
to date act at an upstream level on the Smo receptor [15,16]. Unfortunately, these agents have 
shown many limits [17,18], such as low pharmacokinetic properties and severe side effects, 
including nausea, diarrhea, muscle cramping dysgeusia, fatigue, alopecia, hyponatremia, weight 
loss [19–21]. Vismodegib (Erivedge®, Genentech) and Sonidegib (Odomzo®, Novartis) are two Smo-
antagonists approved by the Food and Drug Administration (FDA) for the treatment of metastatic 
and/or locally advanced BCC [22]. Despite some promising clinical response, treatments with 
Vismodegib or Sonidegib have resulted in aggressive tumor relapse, due to the development of 
resistant tumor clones [14,21,23,24]. 
Vismodegib resistance is prevalently associated with Smo mutation and to a lesser extent with 
alterations of downstream Hh pathway components (SuFu and Gli2) or induction of alternative 
signaling pathways leading to Gli1 activation, such as phosphatidylinositol 3-kinase (PI3K) and 
atypical protein kinase C ι/λ (aPKC-ι/λ) [24]. 
It is known that the Hh pathway can also be activated by Smo-independent mechanisms (i.e., 
gene amplification of Gli factors, mutation of the tumor suppressor SuFu, post-synthetic 
modifications like decreased ubiquitination-mediated degradation or acetylation of the Gli proteins 
or increased PI3K/mTOR/S6K1 kinase-dependent phosphorylation) [25–33] that lead to an increased 
activity of downstream Gli effectors. All mechanisms that act downstream of Smo are alternative 
causes of drug-resistance to the treatment of Hh-driven cancers [34,35]. 
One of the most relevant Hh-dependent tumors is MB, a highly aggressive and heterogeneous 
pediatric brain tumor with a poor clinical outcome [36]. MB has been classified in four major 
molecular subgroups (WNT, SHH, Group 3 and Group 4), each one presenting distinct genetic 
alterations, gene expression landscape and prognosis. Current treatments of MB consist of maximal 
surgical removal of tumor followed by radio- and chemo-therapy that have long-term toxicity 
effects, including delays in physical and cognitive development, a high frequency of relapse and 
increased cardiac risk of diseases [37–39]. 
These issues raise the need to develop new therapeutic strategies, especially focusing on the 
targeting of Hh-signaling. Indeed, the SHH-MB subgroup comprises 25–30% of all MB cases and is 
the best genetically characterized. The use of the Smo-antagonist Vismodegib to treat metastatic MB 
caused tumor relapse in one patient within three months, due to D473H point mutation that 
rendered Smo insensitive to the drug [14,19]. Although two phase II studies suggest the efficacy of 
Vismodegib in recurrent MB [40], the most effective strategy to overcome the drug-resistance 
appears the development of new Hh-inhibitors that counteract this pathway downstream of Smo or 
independently by Smo, as well as to combine different drugs, in a multitargeting approachable to 
inhibit Hh-signaling at multiple levels. 
In this scenario, particular interest has emerged for the development of small molecules as 
inhibitors of Gli1 transcription factor, the final and most powerful positive effector of Hh signaling 
[41]. We have identified and characterized the isoflavone Glabrescione B (GlaB) as a potent and 
direct inhibitor of Gli1/DNA interaction, with strong anticancer efficacy against the Hh-dependent 
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tumorigenesis of BCC and MB [42]. Recently, we exploited the high versatility of the isoflavone 
scaffold for targeting the Hh signaling pathway at multiple levels [43]. In particular, we designed 
and synthesized isoflavones bearing bulky chemical groups in the para position of ring B, with the 
aim to enhance the targeting at the level of the Smo receptor. Similarly, the introduction of bulky 
substitutions in the meta position of the same ring promoted the targeting of the downstream Gli 
effectors. Notably, the simultaneous administration of newly designed isoflavones targeting Smo 
and Gli1 provided synergistic Hh pathway inhibition, which might become relevant to increase the 
barrier to drug resistance, particularly at the level of Smo [43]. In this work, we have designed 
multitarget Hh pathway inhibitors through the combination of the most promising 
pharmacophores targeting Smo and Gli1 in a single and individual isoflavone. Organic synthesis 
and in vitro testing led to the identification of compound 22 as the most efficient multitarget Hh 
inhibitor that antagonizes both Smo and Gli1. This molecule showed strong inhibitory properties on 
Hh signaling as tested in functional and biological in vitro assays and in an in vivo model of Hh-
dependent MB, thus, becoming the first small molecule able to target Hh signaling at multiple 
levels. 
2. Results 
2.1. Design, Synthesis and Functional Screening of Hh Inhibition by Isoflavones 20, 21 and 22 
In a previous study, we demonstrated that the introduction of a bulky substituent in meta or in 
the para position of the isoflavone’s ring B enhanced the specific affinity of these compounds for Gli 
or Smo, respectively, and that their simultaneous administration provided synergistic Hh pathway 
inhibition [43]. In order to develop a multitarget Hh inhibitor, we selected the most promising 
GlaB-ring B derivatives [43] as specific Smo and Gli pharmacophores and combined them in a 
single and individual isoflavone, compound 20 (Figure 1). The ability of this newly synthesized 
isoflavone to inhibit Hh signaling was investigated by a luciferase reporter assay in which NIH3T3 
Shh-Light II cells, stably incorporating a Gli-responsive firefly luciferase reporter (Gli-RE) and the 
pRL-TK Renilla as normalization control, were activated following the treatment with the synthetic 
Smo agonist SAG alone or in combination with compound 20. However, 20 was inactive to 
suppress Hh signaling (Figure S1), probably due to the physicochemical features of the 
trifluoromethyl group. Based on these findings, we designed and synthetized two bioisosters 
featuring methyl (21) and chlororine (22) groups, respectively (Figure 1). For the synthesis of 
compounds 20–22 (Figure S2), we performed the deoxybenzoin approach, a mild and cost-effective 
method that allows the preparation of isoflavones [43]. Compounds 21 and 22 were tested for their 
inhibitory properties on Hh signaling by functional luciferase assay in NIH3T3 Shh-Light II cells as 
described above. Notably, 21 and 22 showed strong Hh pathway inhibition, with 22 being the most 
potent Hh inhibitor of this series with an IC50 of 0.79 µM (Figure 2A,B). 
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Figure 1. Chemical structure of isoflavones 20–22. GlaB-ring B derivatives were designed as 
multitarget Hh inhibitors and synthesized via deoxybenzoin route. O-substitution at meta position 
of ring B (blue) is preferred to interact with Gli, whereas, O-substitution at para position (red) is 
preferred for the interaction with Smo. 
Afterwards, to prove the inhibitory activity of the two newly synthesized isoflavones 21 and 22 
on Hh signaling at the downstream level, we verified their effects on Gli1 transcription activity in a 
Smo-independent condition. To this aim, we treated mouse embryonic fibroblasts (MEFs) 
transiently expressing ectopic Gli1 and a Gli-dependent luciferase reporter, with increasing 
amounts of the two compounds. Both molecules impinge Gli1 function directly, but not Gli1 
exogenous protein levels, with 22 demonstrating a stronger effect (IC50 of 7.00 µM) (Figure 2C,D 
and Figure S3). These results clearly suggest that physicochemical features of substituents to 
isoflavone’s ring B might play a key role in binding to Smo, as well as to Gli1. 
 
Figure 2. Hh inhibition by compounds 21 and 22. The dose-response curve in SAG-treated NIH3T3 
Shh-Light II cells (A,B) or mouse embryonic fibroblasts (MEFs) transfected with 12XGliBS-Luc and 
pRL-TK Renilla (normalization control) plus control (empty) or Gli1 vector (C,D). Cells were treated 
with increasing concentrations of compounds 21 (A,C) and 22 (B,D). Treatment time was 48 h and 
24 h for NIH3T3 Shh-Light II cells and transfected MEFs, respectively. Data were normalized 
against Renilla luciferase. Data show the mean ± SD of three independent experiments. (*) p < 0.05 
vs. SAG or Dimethyl sulfoxide (DMSO); (**) p < 0.01 vs. SAG or DMSO. 
2.2. Inhibitory Effect of Compounds 21 and 22 on Hh-Active Cell Models 
In order to demonstrate the capability of compounds 21 and 22 to target Hh signaling both at 
upstream and downstream level by acting on Smo and Gli respectively, we used Hh-active cell 
models, in which the loss of the main regulators of Hh signaling determines the constitutive 
activation of this pathway. At first, we treated with compounds 21 and 22 Ptch1−/− mouse embryonic 
fibroblasts (Ptch1−/− MEFs), in which the loss of repressive receptor Ptch1 gene constitutively 
induces the activation of Hh signaling, thus, determining high expression levels of Hh target genes, 
including Gli1. The treatment with compound 22 at 1 and 2 µM for 48 h reduced the mRNA levels 
of Gli1 in this cell model stronger than compound 21 used at the same concentrations (Figure 3A). 
Next, to verify the ability of the two isoflavones to inhibit Hh signaling independently of Smo, we 
tested their activity in mouse embryonic fibroblasts lacking the receptor Smoothened (Smo−/− MEFs). 
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Also in this cellular context, compounds 21 and 22, as well as GANT61 and ATO (two well-known 
Gli1 inhibitors), but not the Smo antagonist Vismodegib, were able to reduce the mRNA expression 
levels of Gli1, with an increased effect of 22 compared to 21 (Figure 3B, Figure S4 and Table S1). To 
confirm the inhibitory properties of the two compounds on Hh signaling at Smo downstream level, 
we tested compounds 21 and 22 in SuFu−/− MEFs, in which the loss of the Gli negative regulator 
SuFu leads to the constitutive activation of the pathway. The endogenous expression of Gli1 was 
significantly reduced in these cells after treatment with the two compounds showing, also in this 
case, a stronger efficacy of compound 22 (Figure 3C). These data sustain the ability of the two 
isoflavones to inhibit the Hh signaling both at upstream and downstream levels and identify 
compound 22 as the most effective Hh-inhibitor among the ones we have tested. Moreover, 
compound 22 did not affect WNT or Jun/AP-1 activity supporting its specificity of action for Hh/Gli 
signaling (Figure S5). 
 
Figure 3. Inhibitory effect of compounds 21 and 22 on Hh-active cell models. The graphs show 
mRNA expression levels of Gli1 in Ptch1−/− (A), Smo −/− (B) and SuFu−/− (C) MEFs treated for 48 h with 
DMSO as a control, or compounds 21 or 22 at 1 or 2 µM concentrations. Gli1 mRNA levels were 
normalized to endogenous controls β2-microglobulin and Hprt. Data show the mean ± SD of three 
independent experiments. (*) p < 0.05 vs. DMSO; (**) p < 0.01 vs. DMSO. 
2.3. Molecular Modeling Study on the Interaction between Compound 22 and Smo and Gli1 
To further support the ability of compound 22 to interact with the respective targets Smo and 
Gli1, we performed molecular modeling simulations by using the computational protocols already 
described previously [42–44]. Results clearly show that compound 22 is able to fit the well-known 
antagonists’ site located within the heptahelical bundle of Smo, as well as the isoflavones’ binding 
site located within zinc-finger 4 and zinc-finger 5 of Gli1. In detail, docking of compound 22 to Smo 
by FRED docking program (OpenEye) highlighted a number of H-bond interactions between the 
molecule and Smo key residues, such as Asn219, Gln477, and Arg400 (Figure 4A). The aromatic 
core of the isoflavone’s ring B of 22 is π-π stacked to the side chain of Tyr394, while the p-
chlorophenyl ring substituted in position -para of the isoflavone’s ring B is π-π stacked to His470 in 
a T-shaped configuration (Figure 4A). It is worth noting that this interaction is similar to the 
predicted binding mode of other isoflavones within the Smo antagonists’ site [43]. Molecular 
docking of compound 22 to Gli1 zinc finger was carried out by the GOLD docking program, 
showing that the compound is able to establish a H-bond interaction with Lys350, which has been 
already highlighted in a previous mutagenesis study [42], as well as with the well-known Thr374 
from the nuclear localization signal [45] (Figure 4B). Additional H-bonds are established by 
compound 22 with Thr355 and the Zn-binding His351 (Figure 4B). Further, the binding mode of this 
molecule is highly comparable to that of other isoflavones [42,43]. 
To verify the direct action of compound 22 on Smo receptor we performed a Bodipy-
Cyclopamine (BC) displacement assay using a fluorescent derivate of Cyclopamine that interacts 
with Smo at the level of its heptahelical bundle [46]. To this end, HEK293T cells were transfected 
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with a vector expressing Smo WT or Smo D473H mutant, which confers resistance following 
Vismodegib treatment, and incubated with BC at increasing concentrations of compound 22. As 
shown in Figure 4C, compound 22 displayed similar dose-dependent effects on both WT and 
D473H Smo, indicating its direct binding within the Cyclopamine site of Smo and suggesting its 
potential use for the treatment of Vismodegib-resistant tumors.  
To further confirm molecular modeling results on compound 22 to Gli1 zinc finger domain, we 
verified the effect on Gli1 mutated in Lys340 (K340A), a residue involved in DNA binding and 
transcriptional function of Gli1 [41,42]. As expected, different doses of compound 22 induced a 
moderated reduction of Gli1-dependent transcriptional activation in MEFs WT expressing ectopic 
Gli1 K340A and Gli1-dependent luciferase reporter compared to cells expressing Gli1 WT (Figure 
4D). Of note, by ChIP assay in Gli1-overexpressing MEFs, we observed a significant reduction of 
the Gli1 recruitment into the Ptch1 promoter following the treatment with compound 22 compared 
to control (Figure 4E). According to the high homology degree between the zinc finger domain of 
Gli1 and Gli2, compound 22 also inhibits Gli2-mediated transcription (Figure S6). 
In summary, molecular modeling and biological assays further substantiate the multitarget 
effect of compound 22 by showing that the small molecule is able to fit the ligand-binding site in 
Smo and Gli1, and to interact with residues that are crucial for Hh signaling transduction, without 
affecting ciliogenesis processes or Gli1 subcellular localization (Figure S7A–D, respectively).  
 
Figure 4. Compound 22 directly binds Smo and Gli1. (A,B) Predicted binding mode of compound 22 
to Smo and Gli1. The small molecule is shown as yellow sticks, the proteins as a green cartoon; 
residues within 5 Å from the ligand are shown as lines. Residues contacted by compound 22 are 
shown as sticks and are labeled. Lys340 is shown as sticks as well. H-bond interactions are 
highlighted by magenta dashed lines. (C) The concentration-response curves show the percentage of 
BC binding to WT or D473H Smo mutant after compound 22 treatment. (*) p < 0.05 vs. CTR. (D) 
MEFs WT were transfected with 12XGliBS-Luc and pRL-TK Renilla (as normalization control) plus 
empty vector or WT or K340A Gli1 mutant; 24 h after transfection cells were treated with DMSO 
only or increasing concentrations of compound 22. Luciferase activity was analyzed 24 h after 
treatment. (*) p < 0.05 vs. DMSO, (**) p < 0.01 vs. DMSO; (*) p < 0.05 K340A vs. WT Gli1. (E) MEFs 
WT were transfected with Flag-tagged Gli1 or empty vector and then treated with compound 22 at 
10 µM. Chromatin immunoprecipitation (ChIP) and qRT–PCR using primers surrounding the Gli1-
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binding site (BS) of mouse Ptch1 promoter (schematic representation on the right) were performed. 
Results are indicated as fold difference to empty control. All data show the mean ± S.D. of three 
independent experiments. (*) p < 0.05 vs. empty control. 
2.4. Compound 22 Inhibits the Hh-Dependent Tumor Growth In Vitro 
The aberrant activation of Hh signaling is strongly involved in the onset of several tumors, 
such as medulloblastoma (MB). In order to test the efficacy of isoflavone 22 to suppress the Hh-
dependent tumor growth, we used primary MB cells freshly isolated from Math1-cre/PtchC/C
 
mice 
that spontaneously developed MB and tested in short-term cultures to keep Hh sensitivity in vitro. 
As shown in Figure 5A, compound 22 used at final concentrations of 0.5, 1 and 5 µM, significantly 
inhibits the proliferation of primary MB cells in a dose- and time-dependent manner. This was 
consistent with increased cell death (Figure 5B). Of note, this effect was not observed in Hh-
independent MB cell lines following treatment with compound 22 (Figure S8) [47], indicating its 
selectivity to impair the growth of Hh-MB cells. Consistent with above data, compound 22 reduced 
Gli1 and other Hh pathway target genes (Figure 5C,D) and the endogenous protein levels of Gli1 
and Gli2, but not those of other Hh pathway regulators, such as ERAP1 [48], Itch [49], HDAC1 [30] 
and β-Catenin [50] (Figure 5E,F). 
 
Figure 5. Hh-dependent tumor growth inhibition in vitro by compound 22. (A,B) Primary cell 
cultures from Math1-cre/PtchC/C mice medulloblastoma (MBs) were treated with compound 22 (0.5, 
1 and 5 µM), Vismodegib (0.5 µM) or DMSO only. After the indicated times, a trypan blue count 
was performed to determine the growth rate of viable cells and the percentage of cell death. (C,D) 
Gli1 and Hh target genes mRNA levels of primary MB cells treated with compound 22 determined 
by qRT–PCR and normalized to endogenous control β2-microglobulin and Hprt. (E,F) Representative 
immunoblotting and densitometric analyses of the indicated proteins in primary MB cells after the 
treatment with compound 22. Data show the mean ± SD of three independent experiments. (*) p < 
0.05 vs. DMSO; (**) p < 0.01 vs. DMSO; (***) p < 0.001 vs. DMSO. 
The ability of compound 22 to inhibit tumor cells proliferation and promote cell death was 
confirmed in Med1-MB cell line generated from a spontaneous tumor arisen in a Ptch1+/−; lacZ mouse 
[51,52] (Figure 6A,B). As expected, the treatment with compound 22 significantly reduced mRNA 
expression of Hh target genes and endogenous Gli1 protein levels (Figure 6C,D). To elucidate the 
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anti-proliferative effect of isoflavone 22 also in human cancer cells we used MB Daoy cells, 
belonging to the SHH-MB subgroup [47,53,54]. Compound 22 showed marked activity in inhibiting 
cell proliferation and promoting cell death also at the lower concentration (Figure 6E,F) as a 
consequence of the reduction of the Hh pathway activity (Figure 6G,H). 
 
Figure 6. Mouse Med1-MB (A–D) and human Daoy MB (E–H). Cells were treated with compound 
22 (0.5, 1 and 5 µM) or DMSO only. After the indicated times, a trypan blue count was performed to 
determine the growth rate of viable cells and the percentage of cell death (A,B and E,F). mRNA 
expression levels of the Hh target genes (C,G) and Gli1 protein levels with the corresponding 
densitometric analysis (D,H) were shown. Data show the mean ± SD of three independent 
experiments. (*) p < 0.05 vs. DMSO; (**) p < 0.01 vs. DMSO; (***) p < 0.001 vs. DMSO. 
2.5. Compound 22 Inhibits the Hh-Dependent Tumor Growth In Vivo 
These promising results prompted us to test the ability of isoflavone 22 to inhibit the Hh-
driven tumor growth also in an in vivo allograft model of MB. To this aim, nude mice were grafted 
with spontaneous primary MB cells from Math1-cre/PtchC/C
 
mice and treated every second day with 
s.c. injections of compound 22 at a concentration of 5 mg/kg or solvent only. The tumor growth was 
monitored by caliper during the treatment period, and the tumor mass volumes were measured 
after explant appearing significantly reduced in compound 22-treated mice compare to controls 
(Figure 7A,B). These data correlate with the inhibition of both mRNA and protein expression levels 
of endogenous Hh target genes in treated masses, whereas, protein levels of cleaved PARP are 
increased suggesting apoptotic cell death (Figure 7C–E). Moreover, compound 22-treated tumor 
masses showed reduced cellularity with few MB cells dispersed in a large amount of Masson’s 
staining-mediated blue-labeled connective tissue (Figure 7F), associated with a decreased amount of 
Ki67 positive cells (Figure 7F,G). These findings support the strong anti-tumor activity of 
compound 22 in Hh-dependent MB and underline as the use of one molecule with multitargeting 
properties represents a promising therapeutic strategy to antagonize Hh-signaling and the tumor 
growth driven by this oncogenic pathway. 
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Figure 7. Compound 22 impairs Hh-dependent tumor growth in vivo. (A) BALB/c nude mice 
(nu/nu) were grafted with spontaneous primary MB from Math1-cre/PtcC/C mice. Tumor masses (150 
mm3) were injected with compound 22 or solvent only. Tumor growth was monitored during the 
treatment period. (B) Representative flank allograft average volumes (lower panel) and 
quantification of tumor explants (upper panel). (C) The graphs show mRNA expression levels of 
Gli1, Gli2, N-Myc and PCNA determined by qRT–PCR and normalized to endogenous control β2-
microglobulin and Hprt. (D,E) Western blot and densitometric analysis show Hh target protein and 
proliferation marker expression levels from the tumor masses assayed in B. (F) Hematoxylin/Eosin 
(H&E), Masson’s trichrome and Ki67 staining of representative tumor masses. Scale bar 100 µm. (G) 
Quantification of Ki67 immunohistochemical staining, shown in F. Data show the mean ± S.D. of 
tumor (n = 6) for each treatment. (*) p < 0.05 vs. CTR; (**) p < 0.01 vs. CTR; (***) p < 0.001 vs. CTR. 
3. Discussion 
In this study, we propose a novel mechanism of action for targeting Hh signaling pathway. 
Specifically, taking advantage from our previous work, we have designed an isoflavone with the 
aim to target simultaneously the Hh pathway at both upstream and downstream level, i.e., Smo and 
Gli1 respectively, and identify an innovative approach to limit tumor growth. 
Abnormal Hh reactivation is a hallmark of many cancers, and several germline or somatic 
mutations in the Hh pathway components have been documented in BCC, MB, rhabdomyosarcoma 
(RMS), meningioma and many other tumors. For this reason, Hh signaling has emerged in recent 
years as an attractive target for anticancer therapy [55], and small molecules of both natural and 
synthetic origin have emerged as profitable drugs that target key components of the pathway. The 
majority of Hh modulators developed so far act as antagonists of the upstream Smo receptor, and 
two Smo antagonists (Vismodegib and Sonidegib) have been approved by the FDA for the 
treatment of advanced or metastatic BCC. However, the use of these drugs is strongly limited by 
the emergence of drug-resistance and the occurrence of aberrant Hh activation downstream of Smo 
[56]. Hence, the most efficacy strategy to block Hh signaling in cancer appears to be the 
pharmacological inhibition of the final and most powerful effector Gli1 [41]. However, only the Gli 
antagonist Arsenic trioxide (ATO) has entered clinical evaluation so far. For these reasons, 
innovative, efficacy and less toxic Hh antagonists are urgently needed as therapeutic candidates for 
the treatment of Hh-dependent tumors. Natural compounds represent a significant resource for the 
discovery and development of new Hh inhibitors, as demonstrated in the case of isoflavones, 
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derived from plants of the Leguminosae family [57]. In a recent study, we have exploited the high 
versatility of the isoflavone scaffold, and we demonstrated that the introduction of bulky chemical 
groups in the para position of the isoflavone’s ring B enhances the targeting at the level of the Smo 
receptor. In contrast, bulky substitutions introduced in the meta position of the same ring promote 
the targeting of the downstream Gli effectors. Simultaneous administration of isoflavones targeting 
Smo and Gli provided synergistic Hh pathway inhibition with a reduction of around 20 folds of the 
administered dose, which might be relevant to limit toxic side effects and overcome the Smo-drug 
resistance [43]. 
Here, by combining the most profitable pharmacophores for targeting Smo and Gli1 by 
synthetic isoflavones, we have designed and synthesized the isoflavone 22 acting as a multitarget 
Hh inhibitor that targets both Smo and Gli1 at the same time. Compound 22 was able to inhibit Hh-
dependent tumor growth in human and murine MB cells at sub-micromolar concentration, as a 
consequence of the reduction in Gli1 expression levels. Despite the limitations of intratumoral 
administration (i. e. the invasive nature of the injection itself, the rapid clearance of drugs directly 
applied to the tumor and the development of dose-limiting toxicities in the area surrounding the 
site of injection) isoflavone 22 remarkably showed a strong anti-tumor effect also in vivo by 
suppressing cell proliferation and promoting apoptosis. Molecular modeling further corroborated 
the multitarget mechanism of action of 22, showing that the molecule is able to fit the ligand-
binding site in both Smo and Gli1.  
Overall, these results reveal a valuable form of targeted therapy to increase efficacy and to 
decrease the toxicity of individual anticancer agents. Our findings discover the first multitarget Hh 
inhibitor that impinges the Hh-dependent tumor growth and stands as new potential weapons 
against Hh-driven cancer, such as medulloblastoma, the most malignant childhood brain tumor for 
which poor therapeutic options exist. 
4. Material and Methods 
4.1. General Experimental Methods for the Preparation of Compounds 20–22 
All reagents were commercial and were used without further purification. Chromatography 
was carried out on silica gel (230–400 mesh). All reactions were monitored by thin-layer 
chromatography (TLC), and silica gel plates with fluorescence F254 were used. Melting points were 
taken in open capillaries on a Büchi Melting Point B-545 apparatus and are presented uncorrected. 
1H NMR and 13C NMR spectra were recorded using a Bruker 400 Ultra ShieldTM spectrometer 
(operating at 400 MHz for 1H and 100 MHz for 13C) using tetramethylsilane (TMS) as an internal 
standard. Chemical shifts (d) are reported in parts per million (ppm) and are referenced to CHCl3 
(7.26 ppm for 1H, 77.16 ppm for 13C). All 13CNMR spectra were measured with complete proton 
decoupling. Data for NMR spectra are reported, as follows—s (singlet), d (doublet), t (triplet), q 
(quartet), m (multiplet), br (broad) signal, J coupling constant in Hz. Electron spray ionization mass 
spectra (ESI-MS) were recorded on Bruker BioApex Fourier transform ion cyclotron resonance (FT-
ICR) mass spectrometer. HPLC analysis was performed on a Waters 2690 Separation Module, 
equipped with a Rheodyne Model 8125 20 mL injector and a Model M486 programmable multi-
wavelength detector (PDA). The purity of the sample used in this study was higher than 95% by 
HPLC. HPLC conditions, % and Retention times (Rt) were as follows. Column: Phenomenex Luna 
C18, 5.0 µm (250 × 4.6 mm). Eluent A) water/acetonitrile = 95:5 (v/v). Eluent B) water/acetonitrile = 
5:95 (v/v). Gradient elution: For 0–5 min A: B = 50:50; 5–20 min up to 100% B; 20–25 min to 100% B. 
Flow rate: 1.0 mL/min. PDA detection at 200–400 nm.  
4.2. General Procedure for the Synthesis of Compounds 20–22 
The procedure for the synthesis of isoflavone 4d has been already described in Berardozzi et al. 
[43]. To a solution of the isoflavone (4d) (0.18 mmol, 1.00 equiv.) in acetone (5 mL), K2CO3 (1.8 
mmol, 10.00 equiv.) was added. After stirring for 15 min the corresponding benzyl bromide (0.9 
mmol, 5.00 equiv.) was added drop wise to the mixture and stirred at 45 °C overnight. After 
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removing the acetone in a vacuum, H2O (10 mL) and EtOAc (20 mL) were added, and the aqueous 
phase was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over Na2SO4, 
and finally concentrated under reduced pressure. The residue was purified by Flash 
Chromatography using Petroleum Ether/ EtOAc as eluent to give the corresponding substituted-
isoflavone (20-22). The characterization for all compounds is reported in the SI.  
4.3. Luciferase Reporter Assay 
The Hh-dependent luciferase assay was performed in NIH3T3 Shh-Light II cells, stably 
expressing a Gli-responsive luciferase reporter and the pRL-TK Renilla (normalization control), 
treated for 48 h with SAG (200 nM) and the tested compounds at the indicated concentrations. 
Luciferase and Renilla activities were assayed with a dual-luciferase assay system according to the 
manufacturer’s instructions (Biotium Inc., Hayward, CA, USA). Results were expressed as 
Luciferase/Renilla ratios and represented the mean ± S.D. of three experiments, each performed in 
triplicate. 
4.4. Cell Cultures, Transfection and Treatments 
NIH3T3 Shh-Light II, MEFs WT, Ptch1−/− (kindly provided by M.P. Scott), SuFu−/− and Smo−/− 
(kindly provided by R. Toftgard) MEFs and Med1-MB cells (kindly provided by Yoon-Jae Cho), 
D425 and HDMB03 (kindly provided by V. D’Angiolella) were cultured in DMEM plus 10% FBS. 
Daoy cells (obtained from the American Type Culture Condition, ATCC) were cultured in Eagle’s 
minimum essential medium (MEM) plus 10% FBS. D458, D283 (kindly provided by V. 
D’Angiolella) and D341 (obtained from the American Type Culture Condition, ATCC) were 
maintained in Eagle’s minimum essential medium (MEM) plus 20% FBS. All media contained 1% 
Penicillin-Streptomycin and 1% Glutamine. Primary MB cells were freshly isolated from Math1-
cre/PtchC/C mice. Tumors were collected and mechanically disrupted with fire-polished Pasteur 
pipettes in HBSS with 1% Pen/Strep and treated with DNase (10 µg/mL) for twenty minutes to 
obtain a single-cell suspension. Cells were centrifuged and resuspended in Neurobasal Media-A 
with B27 supplement minus vitamin A, penicillin–streptomycin (1%) and L-glutamine (1%) and 
used for short-term to keep Hh-sensitivity in vitro. Mycoplasma contamination in cell cultures was 
routinely detected by using PCR detection kit (Applied Biological Materials, Richmond, BC, 
Canada). Transient transfections were performed using DreamFectTM Gold transfection reagent (Oz 
Biosciences SAS, Marseille, France). NIH3T3 Shh-Light II cells were treated with SAG (200 nM, 
Alexis Biochemicals Farmingdale, NY, USA) for 48 h. Where indicated, cells were treated with 
Vismodegib (Selleckchem), Arsenic (III) oxide (ATO, Sigma Aldrich, St. Louis, MO, USA) and 
GANT61 (Enzo Life Sciences, Exeter, UK) at the indicated concentrations.  
4.5. Bodipy-Cyclopamine (BC) Binding Assay 
Human Myc-DDK-tagged Smo WT or human Myc-DDK-tagged Smo D473H was transfected 
in HEK293T cells. Cells were washed in PBS supplemented with 0.5% fetal bovine serum, fixed in 
4% paraformaldehyde in phosphate-buffered saline (PBS) for 10 min, and incubated for 2 h at 37 °C 
both in the same medium supplemented with Bodipy-Cyclopamine (5 nM) and the studied 
compounds at indicated concentrations. The cells were permeabilized with 0.2% Triton X100 
(Sigma) 0.2%. Dako Fluorescent mounting (Dako, Carpinteria, CA, USA) was used as a mounting 
medium and Hoechst reagent for staining of the cell nuclei. Bodipy (green) and Hoechst (blue) 
signals were analyzed. 
4.6. mRNA Expression Analysis 
Trizol reagent (Invitrogen/Life Technologies, Carlsbad, CA, USA) was used to isolate total 
RNA from cells and tissues and reverse transcribed with SensiFAST cDNA Synthesis Kit (Bioline 
Reagents Limited, London, UK). Quantitative real-time PCR (Q-PCR) analysis of Gli1, Gli2, Ptch1, 
Hip1, N-Myc, PCNA, β-2 microglobulin and Hprt mRNA expression was performed on each cDNA 
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sample using the VIIA7 Real Time PCR System employing Assay-on-Demand Reagents (Life 
Technologies). FAST Q-PCR thermal cycler parameters were used to amplify the reaction mixtures 
containing cDNA template, SensiFAST Probe Lo-ROX Kit (Bioline Reagents Limited, London, UK) 
and primer probe. Each amplification reaction was performed in triplicate, and the average of the 
three threshold cycles was used to calculate the amount of transcript in the sample (using SDS 
version 2.3 software). mRNA quantification was expressed as the ratio of the genes of interest 
quantity to the housekeeping genes quantity. All values were normalized with two endogenous 
controls, β-2 microglobulin and Hprt. 
4.7. Cell Proliferation Assay 
To determine the growth rate of viable MB cells, a trypan blue count was performed after a 
treatment period of 24–48–72 h with the studied compounds or solvent only used as control. 
4.8. Immunoblot Analysis 
Tissues were lysed in a solution containing RIPA buffer (50 mM Tris-HCl at pH 7.6, 150 mM 
NaCl, 0.5% sodium deoxycholic, 5 mM EDTA, 0.1% SDS, 100 mM NaF, 2 mM NaPPi, 1% NP-40) 
supplemented with protease and phosphatase inhibitors. Lysates were centrifuged at 13,000 × g for 
30 min at 4 °C and the resulting supernatants were subjected to immunoblot analysis with the 
following antibodies: mouse anti-Gli1 (L42B10, 1:500) and rabbit anti-PARP (9542, 1:1000) 
purchased from Cell Signaling (Beverly, MA, USA); rabbit anti-Cyclin D1-20 (sc-717, 1:500), rabbit 
anti-β-Catenin (sc-7199, 1:1000) and goat anti-Actin (sc-1616, 1:1000) were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA); mouse anti-ERAP1 6H9 (1:1000) kindly provided by P. 
van Endert; goat anti-Gli2 (AF3635, 1:1000) was purchased from R&D Systems; mouse anti-Itch 
(611199, 1:1000) antibody was purchased from BD Bioscience (Heidelberg, Germany); rabbit anti-
HDAC1 (H3284, 1:1000) was purchased from Sigma Aldrich (St. Louis, MO, USA). 
4.9. Chromatin Immunoprecipitation 
MEFs WT transfected with Flag-tagged Gli1 plasmid or pcDNA3.1 were crosslinked, and 
chromatin immunoprecipitation was carried out with (1:200) mouse anti Flag-M2 antibody (Sigma 
Aldrich, St. Louis, MO, USA). Eluted DNA was analyzed by qRT-PCR as previously described [42]. 
4.10. Subcellular Fractionation 
Freshly harvested cells were lysed in Buffer A (10 mM HEPES at pH 7.4, 10 mM KCl, 10 mM 
NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF) and centrifuged at 11,000 × g for 20 
min to obtain the cytoplasmic fraction. The nuclear pellet was washed in Buffer B (20 mM HEPES at 
pH 7.4, 20% glycerol, 100 mM KCl, 1 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 10 ng ml−1 Leupeptin) 
and centrifuged at 11,000 × g for 10 s to remove the supernatant. Nuclei were extracted with Buffer 
C (20 mM HEPES at pH 7.4, 20% glycerol, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.5 
mM PMSF, 10 ng ml−1Leupeptin) by centrifugation at 13,000 × g for 10 min. Lysates were analyzed 
by western blotting assay. 
4.11. Immunofluorescence 
For the analysis of ciliogenesis, MEFs WT were treated with compound 22 at several 
concentrations for 24 h in 0.05% FBS and then fixed 10 min in 4% paraformaldehyde. The primary 
antibody for the cilium marker IFT88 (Rabbit Polyclonal 13967-1-AP, from ProteinTech, Manchester, 
UK) was incubated overnight at the dilution (1:200) in blocking solution (2% FBS, 2% BSA, 0.2% fish 
gelatin in PBS1X). A secondary antibody conjugated to Alexa-488 (ThermoFisher Scientific, MA, 
USA) and DAPI for the staining of nuclei, were diluted in blocking solution (1:1000) and incubated 
1 h at room temperature. Images were acquired through 60X oil objective lens (Olympus IX81) 
coupled to a monochrome CCD camera (Sensicam QE; Cooke Corporation, ME, USA). For 
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quantification of IFT88 positive cells and the length of cilia expressed in µm was used ImageJ 
Measure function to count the number of objects and their length. 
4.12. Immunohistochemistry 
For immunohistochemical staining tissues were fixed in formalin and paraffin embedded. 
Sections were incubated with rabbit monoclonal Ki67 antibody (Thermo Fisher Scientific, MA, 
USA) (1:100) diluted in PBS. Detection was carried out with the mouse-to-mouse HRP (DAB) 
staining system (ScyTek Laboratories, Logan, UT, USA) accordingly to the manufacturer’s 
instructions. 
4.13. Molecular Modeling 
The predicted binding mode of compound 22 to Smo and Gli1 was investigated as described 
previously [43]. Briefly, molecular docking to Smo was carried out with FRED version 3.3.0.3 
(OpenEye) (OpenEye Scientific Software, Santa Fe, NM, USA. http://www.eyesopen.com) [58,59], 
using the highest docking resolution, while other parameters were used at their default values. 
Ligand conformational analysis was carried out with OMEGA version 3.1.0.3 (OpenEye) (OpenEye 
Scientific Software, Santa Fe, NM, USA. http://www.eyesopen.com) [46] by storing up to 600 
conformations of the molecule. The crystallographic structure of Smo in complex with cyclopamine 
coded by PDB-ID 4O9R was used as a rigid receptor in docking towards Smo [46]. Docking to Gli1 
zinc finger domain was carried out by GOLD version 5.7.1 (The Cambridge Crystallographic Data 
Centre, Cambridge, UK) [60] using the Goldscore docking function. The crystallographic structure 
of Gli1 in complex with DNA coded by PDB-ID 2GLI was used as a rigid receptor in docking 
towards Gli1 zinc finger domain [61]. 
4.14. Animal Studies 
For allograft experiment, spontaneous MB from Math1-cre/PtchC/C mice was collected, minced 
and pipetted to obtain a single-cell suspension. Equal amounts of cells (2 × 106) were injected s.c. at 
the posterior flank of BALB/c nude mice (nu/nu) (Charles River Laboratories, Lecco, Italy). When 
tumors reached a median size of ~150 mm3, animals were randomly divided into two groups (n = 6) 
and intratumorally injected every second day with compound 22 or solvent only (2-hydroxypropyl-
b-cyclodextrin:DMSO) for 18 days. Tumor growth was monitored and measured with caliper. 
Changes in tumor volume were evaluated with the formula (length × width) × 0.5 × (length + 
width). All animal protocols were approved by local ethic authority (Ministry of Health) and 
conducted in accordance with Italian Governing Law (D.lgs 26/2014). 
4.15. Statistical Analysis 
Statistical analysis was performed using the StatView 4.1 software (Abacus Concepts, Berkeley, 
CA, USA). For in vivo studies, statistical differences were analyzed by Mann-Whitney U-test for 
non-parametric values, and a p value < 0.05 was considered significant. For all other experiments, p 
values were determined using two-tailed Student’s t-test, and statistical significance was set at p < 
0.05. Results are expressed as mean ± S.D. from an appropriate number of experiments (at least 
three biological replicas). 
5. Conclusions 
We designed a modified isoflavone bearing specific substitutions at para or meta position of 
ring B that are preferred for the interaction with Smo or Gli1, respectively. We demonstrated that 
this small molecule, compound 22, is able to target the Hh pathway at both upstream and 
downstream level simultaneously, leading to a marked tumor growth inhibition in a model of Hh-
dependent cancer. Our study provides significant support in oncology research for the 
development of new clinically relevant Hh inhibitors, and encourages the use of a multitargeting 
approach for the treatment of Hh-driven tumors. 
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